Drug-coated balloon-based PCI reduced all-cause mortality from 25% to 6% compared to DES-only PCI in coronary artery disease patients with chronic heart failure over median 3.3 years.
Cohort (n=98)
No
Does drug-coated balloon-based PCI reduce all-cause mortality compared to DES-only PCI in CAD patients with chronic heart failure?
In CAD patients with chronic heart failure, a DCB-based PCI strategy was associated with significantly lower all-cause mortality compared to a DES-only strategy, potentially driven by a reduction in total stent burden.
Absolute Event Rate: 6% vs 25%
p-value: p=0.025
Background: Drug-coated balloon (DCB) is a novel treatment option for percutaneous coronary intervention (PCI). The presence of heart failure (HF) in patients with coronary artery disease (CAD) is associated with a poor prognosis. However, the clinical significance of DCB-based PCI in CAD patients with HF is unknown.
Takahashi et al. (Thu,) conducted a cohort in Coronary artery disease patients with chronic heart failure undergoing percutaneous coronary intervention (n=98). Drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) vs. Drug-eluting stent-only percutaneous coronary intervention (DES-only PCI) was evaluated on All-cause mortality (p=0.025). Drug-coated balloon-based PCI reduced all-cause mortality from 25% to 6% compared to DES-only PCI in coronary artery disease patients with chronic heart failure over median 3.3 years.